Please wait while the formulary information is being retrieved.
GLOPERBA (colchicine)
- treatment to prevent acute gout attack
0.6 mg/5 mL oral solution
- 5 milliliters (0.6 mg) by oral route once daily
Default screening record
- 5 milliliters (0.6 mg) by oral route once daily
- 5 milliliters (0.6 mg) by oral route 2 times per day
- None
Contraindicated
- amiodarone
- amiodarone in dextrose,iso-osm
- amoxicil-clarithromy-lansopraz
- Anti-allergy Formula
- aprepitant
- Aptivus
- ascorbate calcium-B5-quercetin
- atazanavir
- azithromycin
- B3,azel,quer&tur-FA-B6-zn-copp
- Biaxin
- Biaxin Xl
- Biaxin Xl Pak
- Bilberry Extract
- bilberry-rutin-bioflav-quercet
- boceprevir
- Calan
- Calan Sr
- captopril
- captopril-hydrochlorothiazide
- Cardizem
- Cardizem Cd
- Cardizem La
- Cartia Xt
- carvedilol
- carvedilol phosphate
- Cipro
- Cipro In D5W
- Cipro Xr
- ciprofloxacin
- ciprofloxacin (mixture)
- ciprofloxacin in D5W
- clarithromycin
- conivaptan in 5 % dextrose
- Cordarone
- Coreg
- Coreg Cr
- Crixivan
- crizotinib
- cyclosporine
- cyclosporine modified
- darunavir
- dextromethorphan-quinidine
- Diflucan
- Dilacor Xr
- Dilt-xr
- diltiazem HCl
- dronedarone
- elvitegr-cobicist-emtric-tenof
- Emend
- Erythrocin
- erythromycin
- erythromycin-sulfisoxazole
- felodipine
- fluconazole
- fluconazole in dextrose(iso-o)
- fluconazole in NaCl (iso-osm)
- fosamprenavir
- fosaprepitant
- Gengraf
- Gleevec
- imatinib
- Incivek
- indinavir
- Invirase
- itraconazole
- Kaletra
- Ketek
- ketoconazole
- Lexiva
- lopinavir-ritonavir
- Matzim La
- Maximum Daily Green
- Minus Weight Plus Energy
- Multaq
- mv-iron-FA-Ca-beepoln-hb 101
- nefazodone
- nelfinavir
- Neoral
- Nexterone
- Nicazel Forte
- Norvir
- Norvir Soft Gelatin
- Noxafil
- Nuedexta
- Omeclamox-pak
- omeprazole-clarith-amoxicillin
- Onmel
- Pacerone
- posaconazole
- Prevpac
- Prezista
- quinidine gluconate
- quinidine sulfate
- resveratrol-quercetin
- Reyataz
- ritonavir
- Sandimmune
- saquinavir mesylate
- Sporanox
- Sporanox Pulsepak
- Stribild
- Tarka
- Taztia Xt
- telaprevir
- telithromycin
- Tiazac
- tipranavir
- trandolapril-verapamil
- Vaprisol
- verapamil
- Verelan
- Verelan Pm
- Vfend
- Vfend Iv
- Victrelis
- Viracept
- vit C-B6-B5-magnesium-hrb #173
- voriconazole
- Xalkori
- Xydra Ef
- Zithromax
- Zithromax Tri-pak
- Zithromax Z-pak
- Zmax
Severe
Moderate
- Advicor
- Altoprev
- amlodipine-atorvastatin
- Antara
- atorvastatin
- Caduet
- ezetimibe-atorvastatin
- ezetimibe-simvastatin
- fenofibrate
- fenofibrate micronized
- fenofibrate nanocrystallized
- fenofibric acid
- fenofibric acid (choline)
- Fenoglide
- Fibricor
- fluvastatin
- gemfibrozil
- Lescol
- Lescol Xl
- Lipitor
- Lipofen
- Liptruzet
- Lofibra
- Lopid
- lovastatin
- Mevacor
- niacin-lovastatin
- niacin-simvastatin
- Pravachol
- pravastatin
- Simcor
- simvastatin
- Tricor
- Triglide
- Trilipix
- Vytorin 10-10
- Vytorin 10-20
- Vytorin 10-40
- Vytorin 10-80
- Zocor
- Hemolytic anemia from pyruvate kinase and g6PD deficienc
Contraindicated
- Aplastic anemia
- Renal dialysis
- Severe hepatic disease
- Severe renal impairment
Severe
Moderate
- Bone marrow depression
- Diarrhea
- Granulocytopenic disorder
- Leukopenia
- Myopathy
- Rhabdomyolysis
- Thrombocytopenic disorder
- Vomiting
GLOPERBA (colchicine)
- treatment to prevent acute gout attack
- None
- Abdominal pain with cramps
- Diarrhea
- Nausea
- Sore throat
- Vomiting
More Frequent
Severe
Less Severe
- None
- Headache disorder
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Agranulocytosis
- Allergic dermatitis
- Angioedema
- Aplastic anemia
- Bone marrow depression
- Disseminated intravascular coagulation
- Increased alanine transaminase
- Increased aspartate transaminase
- Leukopenia
- Myopathy
- Pancytopenia
- Peripheral motor neuropathy
- Purpura
- Rhabdomyolysis
- Skin rash
- Thrombocytopenic disorder
- Urticaria
Less Severe
- Alopecia
- Azoospermia
- Maculopapular rash
- Oligospermia
- Peripheral sensory neuropathy
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Colchicine (Oral Solution)
Safety and effectiveness not established in pediatric patients.
- 1 Day – 18 Years
- Safety and effectiveness not established in pediatric patients.
Colchicine
- Severity Level:
2
- Additional Notes: Available human data show no increased risk for major birth defects
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Colchicine
Limited data suggest no infant adverse effects with chronic treatment
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited data suggest no infant adverse effects with chronic treatment |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Colchicine
Renal-Elderly more susceptible to cumulative toxicity with decreased renal function. Reduce dose for CrCL < 30 mL/min
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: Y HEDIS: N STOPP: Y
No Known Risk
None
- None
| Prevention of acute gout attack | |
| E79.0 | Hyperuricemia without signs of inflammatory arthritis and tophaceous disease |
| M10 | Gout |
| M10.00 | Idiopathic gout, unspecified site |
| M10.30 | Gout due to renal impairment, unspecified site |
| M10.40 | Other secondary gout, unspecified site |
| M10.9 | Gout, unspecified |
| M1A.00x1 | Idiopathic chronic gout, unspecified site, with tophus (tophi) |
| M1A.20x1 | Drug-induced chronic gout, unspecified site, with tophus (tophi) |
| M1A.30x1 | Chronic gout due to renal impairment, unspecified site, with tophus (tophi) |
| M1A.40x1 | Other secondary chronic gout, unspecified site, with tophus (tophi) |
| M1A.9xx0 | Chronic gout, unspecified, without tophus (tophi) |
| M1A.9xx1 | Chronic gout, unspecified, with tophus (tophi) |
| 0-9 | A-Z |
|---|---|
| E79.0 | Hyperuricemia without signs of inflammatory arthritis and tophaceous disease |
| M10 | Gout |
| M10.00 | Idiopathic gout, unspecified site |
| M10.30 | Gout due to renal impairment, unspecified site |
| M10.40 | Other secondary gout, unspecified site |
| M10.9 | Gout, unspecified |
| M1A.00x1 | Idiopathic chronic gout, unspecified site, with tophus (tophi) |
| M1A.20x1 | Drug-induced chronic gout, unspecified site, with tophus (tophi) |
| M1A.30x1 | Chronic gout due to renal impairment, unspecified site, with tophus (tophi) |
| M1A.40x1 | Other secondary chronic gout, unspecified site, with tophus (tophi) |
| M1A.9xx0 | Chronic gout, unspecified, without tophus (tophi) |
| M1A.9xx1 | Chronic gout, unspecified, with tophus (tophi) |
Formulary Reference Tool